Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours Β· Estimated delivery Aug 10 - Aug 15
Start your intake Where Hers sits in the GLP-1 telehealth field Hers is the women-focused arm of Hims & Hers Health, a publicly traded direct-to-consumer telehealth company
The most common denial reasons are insufficient documentation of the required 90-day lifestyle intervention (41% of denials), BMI not meeting threshold or comorbidity not documented (28%), step therapy not completed (19%), or prescriber qualification issues (12%)
A 2021 review examining NNMT as a drug target explicitly notes that NNMT-inhibitor drugs remain limited in clinical use and that the field is still working out selectivity and delivery
At the time of the 2025 Super Bowl, there was a shortage of the branded GLP-1 drugs semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound, which opened the door for compounding pharmacies to sell non-identical versions under specific FDA regulations
Learn more about the quality standards, manufacturing practices, and sourcing controls behind NuMedica professional-grade supplements
